Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Respiratory syncytial virus (RSV) is a major cause of virus-induced respiratory disease and hospitalization in infants. Palivizumab, an RSV-neutralizing monoclonal antibody, is used clinically to prevent serious RSV-related respiratory disease in high-risk infants. Motavizumab, an affinity-optimized version of palivizumab, was developed to improve protection against RSV. These antibodies bind RSV F protein, which plays a role in virus attachment and mediates fusion. Determining how these antibodies neutralize RSV is important to help guide development of new antibody drugs against RSV and, potentially, other viruses. This study aims to uncover the mechanism(s) by which palivizumab and motavizumab neutralize RSV. Assays were developed to test the effects of these antibodies at distinct steps during RSV replication. Pretreatment of virus with palivizumab or motavizumab did not inhibit virus attachment or the ability of F protein to interact with the target cell membrane. However, pretreatment of virus with either of these antibodies resulted in the absence of detectable viral transcription. These results show that palivizumab and motavizumab act at a point after F protein initiates interaction with the cell membrane and before virus transcription. Palivizumab and motavizumab also inhibited F protein-mediated cell-to-cell fusion. Therefore, these results strongly suggest that these antibodies block both cell-to-cell and virus-to-cell fusion, since these processes are likely similar. Finally, palivizumab and motavizumab did not reduce viral budding. Based on models developed from numerous studies of viral fusion proteins, our results indicate that these antibodies may prevent conformational changes in F protein required for the fusion process.
Huang
Kelly
K
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA. huangk@medimmune.com
Incognito
Len
L
Cheng
Xing
X
Ulbrandt
Nancy D
ND
Wu
Herren
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D002459:Cell Fusion; D002460:Cell Line; D002522:Chlorocebus aethiops; D006801:Humans; D000069455:Palivizumab; D011485:Protein Binding; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000276:immunology; D014760:Viral Fusion Proteins / Q000276:immunology / Q000378:metabolism; D053585:Virus Attachment / Q000187:drug effects; D053586:Virus Internalization / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D000998:Antiviral Agents; C526850:F protein, human respiratory syncytial virus; D014760:Viral Fusion Proteins; C506968:motavizumab; D000069455:Palivizumab